Two lyophilized control sera were distributed through seven national external quality assessment schemes in six European countries-Belgium, Switzerland, France, The Netherlands, Sweden and the United Kingdom-participated in the study. The results for 17 routine analytes were obtained from almost 5000 laboratories for the two sera. The organizers of the schemes were asked to process the results according to a common outlier removal procedure, and submit methodrelated data if available. The two sera were also distributed through the external/internal scheme of The Netherlands, and the within-laboratory standard deviations calculated in this scheme have been used in a scaling procedure for the external mean values and between-laboratory standard deviations of the participating countries.
Assessment Schemes (NEQASs) are operational in the various countries. Many papers have been published on the performances of the schemes and the improvements achieved.':" However, information on the interlaboratory comparability among countries is scarce. Most of the work done on intercomparison between countries has been confined to small groups of laboratories. The idea of distributing the same specimens to all participants through the schemes of several nations arose at the International Federation of Clinical Chemistry (IFCC) congress in The Hague in 1987.Organisers of NEQASs of seven countries were asked to incorporate two lyophilized sera, kindly donated by Nycomed AS (Norway), in their schemes. Analytical data from six countries were obtained between 1988 and 1990. Countries that participated in the study are Belgium (B), Switzerland (CH), France (F), The Netherlands (NL), Sweden (S) (two schemes) and the United Kingdom (UK). Full titles of the participating schemes are listed in the appendix.
The organizers were asked to process their data according to a common outlier rejection procedure, as in other similar studies" and to submit information on the analytical methods used if possible. The results obtained for 17 analytes are reported in this paper.
MATERIALS AND METHODS
Two lyophilized bovine sera (Seronorm 179 and Pathonorm H-22, Nycomed AS, Norway) having different analyte levels were distributed through seven established NEQAS schemes of six countries. Sweden participated with two schemes, the Uppsala and the West Sweden schemes. The number of participating laboratories returning results in the various NEQASs differed widely: Belgium 265, Switzerland 146, France 3839, Netherlands 197, Sweden (Uppsala) 17, Sweden (West) 58, UK 484. Since the number of participating laboratories in each of the two Swedish schemes was small, the data from all Swedish laboratories has been reprocessed to produce nationwide results. Information on the analytical methods used was obtained from Belgium, France, The Netherlands, and the UK. However for several analytes the method definition of the UK scheme differed too much from those of the other countries to incorporate the UK results in the method-related computations.
The organizers of the NEQAS schemes of the participating countries were asked to process their data according to a common procedure for estimation of the population mean and standard deviation (SD).8 In summary, this involved trimming the results at 2· 5 and 97' 5010; computation of the population standard deviation; two further truncations at mean ± 2 SD; computation of the population mean value. A nonweighted 'European' grand mean value was computed from the national mean values for each analyte to obtain a reference point for the graphical presentations. National means are compared to the grand mean in a t-test of means using the national SD as an estimate of the population SD.
The two sera were also distributed through the internal/external scheme of The Netherlands.~In this scheme about 80 laboratories analysed the two sera daily over 8 weeks. From these results the attainable within-laboratory variance and standard deviation was computed for each serum. The between-laboratories variance of each control material for each country was tested in a F-test against this within-laboratory variance. The bias of the population mean to the grand mean and the between-laboratory SD of each country were then scaled to the grand mean value and the attainable within-laboratory SD as follows:
in which & = grand mean for control material j U= 1,2); Xij =mean value of country i (i = 1,6) for control material j; SD j wl = within-laboratory SD for control material j; SD jj b1 = betweenlaboratory SD of country i for control materialj.
The method group mean values and SDs were scaled in the same manner as the overall values. A total of 17 analytes were analysed in the two control sera: sodium, potassium, chloride, urea, creatinine, urate, glucose, cholesterol, calcium, phosphate, magnesium, iron, bilirubin, total protein, aspartate transaminase (AST) , lactate dehydrogenase (LD) and alkaline phosphatase (ALP). Method-related results are presented here for sodium, potassium, chloride, urea, urate, calcium, phosphate, magnesium and iron. For the enzymes only results from countries that used comparable method definitions have been taken into consideration. The two control sera have been analysed for cholesterol by the CDC modified Abell-Kendall Reference method? in the Netherlands Lipid Reference Center in Rotterdam.
RESULTS AND DISCUSSION
The results obtained from the external/internal programme of the Netherlands are presented in Table 1 . The within-laboratory SDs found are comparable to values published previously.! indicating that the control materials distributed were homogeneous and did not show any timedependent variation within a two month interval. The national means and SDs are scaled to these within-laboratory SDs, to render results of the two control sera comparable and also to express the between-laboratory SDs as multiples of the attained within-laboratory SD. Ideally, there should be no between-laboratory component of variation, and the national SDs should thus be equal to the within-laboratory component. As the results of individual laboratories could not be examined, no conclusions can be drawn on the variability of individual biases. Thus it is not clear whether laboratories having a negative bias for Seronorm show the same bias for Pathonorm. For all analytes the national mean values appeared to be well comparable and in most instances are within one within-laboratory SD from the grand mean. The differences are however statistically significant in practically all cases, mainly because of the large number of laboratories.
Sodium, potassium and chloride
Results for sodium, potassium and chloride are presented in Fig. 1 ; no results for sodium or chloride were obtained from Belgium. There are relatively large differences between the national between-laboratory SDs. All of the betweenlaboratory SDs differ significantly from the within-laboratory SD, except for the results of The Netherlands for potassium. There is considerable variability in the SD from country to country. Between-laboratory SDs in The Netherlands are smaller than in other countries Ann Clin Biochem 1993: 30 for all three analytes, whereas larger interlaboratory variations appear to exist in Switzerland and France, particularly for chloride. The scaled results show the comparability of the results for Seronorm and Pathonorm. In almost all instances the national mean values for the two control materials show the same bias and the same magnitude of SD, though the SDs at the higher level seem to be somewhat larger.
Interpreting the results for sodium in a more practical way, a serum having a concentration of 160 mmollL analysed in two laboratories in Switzerland measuring at the 2'5010 and 97'5% percentiles of the Gaussian distribution would be 154 and 166 mmol/L, respectively. The corresponding figures in The Netherlands would be 157 and 163 mmollL.
The method-related data obtained from Belgium (potassium only), France, The Netherlands and the UK show a positive bias of the direct ion selective electrodes relative to the overall mean of a country, for sodium and potassium in these countries for Pathonorm. For Seronorm only the results of The Netherlands show a positive bias. From a theoretical point of view a positive bias would be expected, but built in factors to 'compensate' for the difference between the measured activity per litre plasma are also operating. The indirect ISE method groups show biases comparable to the overall results in Belgium, France, The Netherlands and the UK. The between-laboratory SDs within method groups are comparable to the overall .5IcI 
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Glucose and cbolesterol
Results for glucose and cholesterol are shown in Fig. 3 . Again the national mean values are very closely comparable in practice, though in many cases showing statistically significant differences from the grand mean. In each country the biases for Seronorm and Pathonorm are very alike for both analytes. Differencesare visible in the between-laboratory SOs for glucose between the participating countries, with The Netherlands and the UK showing smaller interlaboratory variation. In all countries the between-laboratory SOs are less than three times the within-laboratories SO. Table / ). No analytical method groups are differentiated. 0 = Seronorm; • = Pathonorm. the percentages of laboratories that meet the WHO criteria for a single measurement can be calculated. Table 2 summarizes these percentages for the two control sera; the laboratories meeting the criteria for Seronorm are not necessarily the same as those meeting the Pathonorm criteria. Since no information on the individual withinlaboratory SO was obtained, no conclusions can be drawn concerning the compliance with criteria by individual laboratories. In accordance with the bias of the mean values and the broadness of the distribution, as seen in Fig. 3 , for Pathonorm Belgium has the lowest percentage of laboratories
The Netherlands Lipid Reference Center has assigned cholesterol values to the two control sera. These values are 2·05 mmol/L for Seronorm and 6·00 mmol/L for Pathonorm. The grand mean values are respectively 6·8010 and 2'8010 higher than the assigned values. The Swedish results are about 2010 lower than the grand mean. The between-laboratory SOs vary between the countries, Belgium and Switzerland showing slightly larger variation than the other countries. For cholesterol also in all countries the betweenlaboratory SOs are less than three times the within-laboratories so. Although the cholesterol level of Seronorm is low and clinically less interesting, the WHO has set criteria even at this level. The WHO criteria'? at the level of meeting the WHO criteria and Sweden the highest (see Table 2 ).
Caldum, pbospbate and magnesium Figure 4 shows the results for calcium, phosphate and magnesium. Table I ). Analytical method groups and number ofURrs-/ron: direct colorimetric (~) 2/77 (FJ, 82 (NL); AAS (~) JJ (F); 0 «Seronorm; • =Pathornorm.
For calcium, results for three method groups are shown: colorimetric techniques, EOT A titration and atomic absorption spectrometry (AAS). A negative bias from the national mean is apparent for the titrimetric method, particularly for Pathonorm, suggesting that this method may not be linear in the higher range. The AAS method, which is supposed to be free of bias, shows varying behaviour in the three countries that submitted results for it: in France the AAS means for Seronorm and Pathonorm are close to the overall means; in The Netherlands the AAS means are higher and in the UK the mean for Seronorm is comparable to the national mean whereas for Pathonorm a lower mean is found.
It is not clear whether this is caused by the AAS method or by bias of the national means, which are mainly influenced by the colorimetric methods. In France and The Netherlands the betweenlaboratory SOs of the titrimetric groups, and in The Netherlands the AAS group also, are considerably smaller than those of the colorimetric group, which are comparable to the overall results. In the UK the between-laboratory SOSof the three method groups and overall are of the same magnitude, except for the titrimetric group for Pathonorm, which shows a smaller SO.
For phosphate the methods applying no reducing step and those with reduction are differentiated. The performances of these method AST, LD and ALP The results obtained for three enzymes are shown in Fig. 6 . For each enzyme one method group has been selected on the basis that it was applied by a considerable number of laboratories, had the same description in the countries that submitted method related data and within-laboratory SD data were available for scaling purposes. As examples results are presented of the IFCC recommended method for AST at 30 DC, the SFBC recommended method for LD at 30 DC and the method for ALP employing AMP buffer at 30 DC, as submitted by France and The Netherlands. The concentration levels of the enzymes are clinically relevant and differ acceptably for the two control materials. The mean values for AST and ALP in France and The Netherlands are very close and do not differ significantly at the 10/0 uncertainty level from the grand mean. For LD the means between the two countries differ more, however they are still reasonably comparable. For each enzyme a comparable bias is found for Seronorm and Pathonorm in both countries. The between-laboratory SDs for France are larger than for The Netherlands for the selected methods of all three analytes. Since no results from individual laboratories were obtained it was not possible to use, for example, Seronorm as a 'calibrant' for Pathonorm results, as used in previous investigations10,11 to reduce betweenlaboratory variability.
CONCLUSIONS
The comparison of quality assessment results between countries has been a topic of interest for some time, but the opening of the borders in the European Community in 1993 and the associated free exchange of laboratory services brings new relevance to the intercomparison of data. The present investigation in six countries contains the results of many thousands of laboratories. The two control sera used have been distributed through the NEQASs of Belgium, Switzerland, France, The Netherlands, Sweden and the UK, and the same outlier removal procedure was used throughout. Distribution of the control sera through the Netherlands external/internal scheme has provided within-laboratory SDs from the 80 participating laboratories that analysed the sera daily for eight weeks. These have been used in the scaling procedure and the bias of the mean and the between-laboratory SD have been expressed as multiples of the within-laboratory SD as attained in The Netherlands.
The mean values from the six countries for both sera appeared to be remarkably comparable for practically all of the 17 analytes studied. However, the between-laboratory variation differed widely from country to country. The Netherlands, Sweden and the UK have considerably smaller between-laboratory SDs than Belgium, Switzerland and France for many analytes,
No information has been obtained on the within-laboratory variation of individuallaboratories, which is normally (but not necessarily) smaller than the between-laboratory differences. Between-laboratory variation should be reflected in the reference ranges used by individual laboratories.
In some countries (Belgium for instance) enzyme results are submitted as multiples of the individual reference range. However, it seems more appropriate to obtain comparable absolute values, since these are used by the clinicians, and ideally the only factor influencing reference ranges should be the population served. This may be accomplished for instance by using standard reference materials.P'!' The results of France and the Netherlands for three enzymes indicate that large interlaboratory variations exist even if only recommended method groups are considered.
At present much effort is put in the standardization and normalization of more 'difficult' analytes like cortisol and parathyroid hormone. The results presented in this paper indicate that there is still work to be done on those analytes frequently considered as simple and routine. The results of many laboratories appear not to be mutually commutable, indicating the continuing need for EQA and other quality assurance procedures to improve agreement within countries. Compared to the variations between laboratories the variations between countries are small and suggest that mutual recognition of all-method mean values in NEQASs could be acceptable for intercomparis on between countries and between laboratories, especially for analytes where reliable reference methods are not available. batches of Seronorm and Pathonorm. We also thank Dr G J M Boerma (Rotterdam) for supplying the cholesterol reference method values. UK NEQAS is supported by the UK Department of Health. 
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